Mirk-IN-1 is primarily utilized in the field of cancer research due to its ability to inhibit the kinase activity of DYRK1B, a protein that plays a significant role in cell survival and proliferation. This compound is particularly valuable in studying the mechanisms of drug resistance in cancer cells, as DYRK1B is often overexpressed in various cancers, including pancreatic, ovarian, and colon cancers. By inhibiting DYRK1B, Mirk-IN-1 can potentially reduce the survival of cancer cells and enhance the efficacy of other chemotherapeutic agents. Researchers also employ Mirk-IN-1 to explore its potential in combination therapies, aiming to overcome resistance and improve treatment outcomes in aggressive cancers. Its application extends to preclinical studies where it aids in understanding the molecular pathways involved in tumor progression and survival.